- Entheon Biomedical Corp. announced that the company has commenced trading on the Canadian Securities Exchange under the symbol “ENBI”.
Entheon Biomedical Corp. (CSE: ENBI) (formerly, MPV Exploration Inc.) (“Entheon” or the “Company”) is pleased to announce that, further to its news release dated November 5, 2020, the Company has commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “ENBI”.
We are thrilled by the opportunity that listing on the CSE presents. Addiction is a massive societal issue that can no longer be ignored. We are confident that our mission of developing safe and effective psychedelic treatments for those suffering from life-altering addictions will resonate with investors, and they will see not only the value and opportunity, but also the possibility of positively impacting society.”Timothy Ko – CEO of Entheon
Entheon’s share capitalization consists of an unlimited amount of authorized shares, of which 40,388,851 are outstanding and 51,830,618 on a fully-diluted basis.
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
For more information, please contact the Company at:
For media inquiries, please contact Crystal Quast at:
Telephone: +1 (647) 529-6364
Cautionary Note on Forward Looking Information
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the commencement of trading of the Resulting Issuer Shares on the CSE, and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to raise further capital and the Company’s ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.